Synthesis and Biological Activity of Sulfonamide Derivatives of Epipodophyllotoxin

Journal of Medicinal Chemistry

Volumn 47, Issue 9, 2004, Pages 2365-2374

  Guianvarc'h, Dominique ^a   Duca, Maria ^a,b   Boukarim, Chawki ^b   Kraus Berthier, Laurence ^c   Léonce, Stéphane ^c   Pierré, Alain ^c   Pfeiffer, Bruno ^d   Renard, Pierre ^d   Arimondo, Paola B ^a   Monneret, Claude ^b   Dauzonne, Daniel ^b  

^a MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^b CNRS   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4' O NOR 4 DESOXYPODOPHYLLOTOXIN; 4BETA (3 AMINOPROPYL)SULFONAMIDO 4' O NOR 4 DESOXYPODOPHYLLOTOXIN; 4BETA (3 AZIDOPROPYL)SULFONAMIDO 4' O NOR 4 DESOXYPODOPHYLLOTOXIN; 4BETA (4 METHYLPIPERAZINYL)SULFONAMIDO 4' O NOR 4 DESOXYPODOPHYLLOTOXIN; 4BETA DIMETHYLAMINOSULFONAMIDO 4' O NOR 4 DESOXYPODOPHYLLOTOXIN; 4BETA HEXADECYLSULFONAMIDO 4' O NOR 4 DESOXYPODOPHYLLOTOXIN; 4BETA METHYLSULFONAMIDO 4' O NOR 4 DESOXYPODOPHYLLOTOXIN; 4BETA MORPHOLINOSULFONAMIDO 4' O NOR 4 DESOXYPODOPHYLLOTOXIN; 4BETA OCTYLSULFONAMIDO O NOR 4 DESOXYPODOPHYLLOTOXIN; 4BETA PIPERIDINOSULFONAMIDO 4' O NOR 4 DESOXYPODOPHYLLOTOXIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; SULFONAMIDE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CARCINOMA; MOUSE; NONHUMAN; POLYMERIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PODOPHYLLOTOXIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 11144353698     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031117b     Document Type: Article

References (34)

1. Slevin, M. L. The clinical pharmacology of etoposide. Cancer 1991, 67, 319-329.
2. Hande, K. R. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 1998, 34, 1514-1521.
3. Chabner, B. A.; Longo, D. L. Cancer chemotherapy and biotherapy. Principles and practice, 2nd ed.; Lippincott-Raven Publishers: New York, 1996.
4. Monneret, C.; Daley, L. Nouveaux analogues hydrosolubles de l'étoposide. Actualités Chim. Thér. 1997, 23, 267-279.
5. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65, 635-692.
6. Burden, D. A.; Osheroff, N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400, 139-154.
7. Leroy, D.; Kajava, A. V.; Frei, C.; Gasser, S. M. Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry 2001, 40, 1624-1634.
8. Pedersen-Bjergaard, J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leuk. Res. 1992, 16, 61-65.
9. Felix, C. A. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta 1998, 1400, 233-255.
10. Lazo, J. S.; Li, T.; Woo, E. S.; Settineri, C. E.; Allan, W. P.; Yalovich, J. C. Chemical synthesis and biological activity of a novel fluorescent etoposide derivative. Biochem. Pharmacol. 1997, 53, 715-722.
11. Zhu, X.-K.; Guan, J.; Tachibana, Y.; Bastow, K. F.; Cho, S. J. Cheng, H.-H.; Cheng, Y.-C.; Gurwith, M.; Lee, K.-H. Antitumor agents. 194. Synthesis and biological evaluations of 4β-mono-, -di-, and -trisubstituted aniline-4′-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles. J. Med. Chem. 1999, 42, 2441-2446.
12. Xiao, Z.; Xiao, Y.-D.; Feng, J.; Golbraikh, A.; Tropsha, A.; Lee, K.-H. Antitumor agents. 213. Modeling of epipodophyllotoxin derivatives using variable selection k nearest neighbor QSAR method. J. Med. Chem. 2002, 45, 2294-2309.
13. Saito, H.; Yoshikawa, H.; Nishimura, Y.; Kondo, S.; Takeuchi, T.; Umezawa, H. Studies on lignan lactone antitumor agents. II. Synthesis of N-alkylamino- and 2,6-dideoxy-2-aminoglycosidic lignan variants related to podophyllotoxin. Chem. Pharm. Bull. 1986, 34, 3741-3746.
14. Daley, L.; Guminski, Y.; Demerseman, P.; Kruczynski, A.; Etievant, C.; Imbert, T.; Hill, B. T.; Monneret, C. Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611. J. Med. Chem. 1998, 41, 4475-4485.
15. Zheng, J.; Wang, H.-K.; Bastow, K. F.; Zhu, X.-K.; Cho, S. J.; Cheng, Y.-C.; Lee, K.-H. Antitumor agents. 177. Design, syntheses, and biological evaluation of novel etoposide analogues bearing pyrrolecarboxamidino group as DNA topoisomerase II inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 607-612.
16. Lee, K.-H.; Wang, H.-K. Antitumor agents. 165. Current status of bioanalysis of etoposide and related compounds. J. Food Drug Anal. 1995, 3, 209-232.
17. Macdonald, T. L.; Lehnert, E. K.; Loper, J. T.; Chow, K.-C.; Ross, W. E. DNA topoisomerases in Cancer; Oxford University Press: New York, 1991; pp 199-214.
18. Fossé, P.; René, B.; Saucier, J. M.; Henichart, J. P.; Waring, M. J.; Colson, P.; Houssier, C.; Bailly, C. Stimulation of site-specific topoisomerase II-mediated DNA cleavage by an N-methylpyrrolecarboxamide-anilinoacridine conjugate: Relation to DNA binding. Biochemistry 1994, 33, 9865-9874.
19. René, B.; Fossé, P.; Khélifa, T.; Jacquemin-Sablon, A.; Bailly, C. The 1′-substituent on the anilino ring of the antitumour drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Mol. Pharmacol. 1996, 49, 343-350.
20. Arimondo, P.; Boukarim, C.; Bailly, C.; Dauzonne, D.; Monneret, C. Design of two etoposide-amsacrine conjugates: Topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anti-Cancer Drug Design 2000, 15, 413-421.
21. Imbert, T.; Guminski Y. Method for preparing 4′ -demethylepipodophyllotoxin from podophyllotoxin. PCT Int. Appl. WO 97 21, 713 (Cl. CO7D493/04), 19 Jun 97; Fr. appl. 95/14, 875, 14 Dec 1995; pp 20 (Fr). Chem. Abstr. 1997, 127, 121598a.
22. Zhou, X.-M.; Wang, Z.-Q.; Chang, J.-Y.; Chen, H.-X.; Cheng, Y.-C. Lee, K.-H. Antitumor agents. 120. New 4-substituted benzylamine and benzyl ether derivatives of 4′-O-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II. J. Med. Chem. 1991, 34, 3346-3350.
23. Chen, M.; Beck, W. T. Differences in inhibition of chromosome reparation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res. 1995, 55, 1509-1516.
24. Guilbaud, N.; Kraus-Berthier, L.; Meyer-Losic, F.; Malivet, V.; Chacun, C.; Jan, M.; Tillequin, F.; Michel, S.; Koch, M.; Pfeiffer, B.; Atassi, G.; Hickman, J.; Pierré, A. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Clin. Cancer Res. 2001, 7, 2573-2580.
25. Binkley, W. W.; Degering, E. F. Organic syntheses with sulfuryl chloride. J. Am. Chem. Soc. 1939, 61, 3250-3251.
26. Chatterjee, S.; Ator, M. A.; Bozyczko-Coyne, D.; Josef, K.; Wells, G.; Tripathy, R.; Iqbal, M.; Bihovsky, R.; Senadhi, S. E.; Mallya, S.; O'Kane, T. M.; McKenna, B. A.; Siman, R.; John, P.; Mallamo, J. P. Synthesis and biological activity of a series of potent fluoromethyl ketone inhibitors of recombinant human calpain I. J. Med. Chem. 1997, 40, 3820-3828.
27. Denivelle, L. Action de l'ammoniac et des amines sur les chlorosulfates d'aryle et les N-chlorosulfonyl-sulfonamides. Bull. Soc. Chim. Fr. 1936, 3, 2143-2152.
28. Matier, W. L.; Comer, W. T. Sulfamoyl azides. Hydrolysis rates and hypotensive activity. J. Med. Chem. 1972, 15, 538-541.
29. Leonce, S.; Anstett, M.; Combe-Perez, V.; Pierre, A. Flow cytometric evaluation of the cell cycle perturbations induced by S12363, a new vinca alkaloid derivative. Anti-Cancer Drugs 1990, 1, 179-183.
30. Pierré, A.; Perez, V.; Leonce, S.; Boutin, J. A.; Saint-Dizier, D.; Hautefaye, P.; Lavielle, G.; Atassi, G. Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative. Cancer Chemother. Pharmacol. 1992, 29, 367-374.
31. Guilbaud, N.; Kraus-Berthier, L.; Saint-Dizier, D.; Rouillon, M. H.; Jan, M.; Burbridge, M.; Visalli, M.; Bisagni, E.; Pierré, A.; Atassi, G. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer Chemother. Pharmacol. 1996, 38, 513-521.
32. Kraus-Berthier, L.; Jan, M.; Guilbaud, N.; Naze, M.; Pierré, A.; Atassi, G. Histology and sensitivity to anticancer drugs of two human nonsmall cell lung carcinomas implanted in the pleural cavity of nude mice. Clin. Cancer Res. 2000, 6, 297-304.
33. Workman, P.; Balmain, A.; Hickman, J. A.; McNally, N. J.; Rohas, A. M.; Mitchinson, N. A.; Pierrepoint, C. G.; Raymond, R.; Rowlatt, C.; Stephens, T. C.; Wallace, J.; Straughan, D. W. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab. Anim. 1988, 22, 195-201.
34. Zavala; F.; Guenard, D.; Robin, J.-P.; Brown, E. Structure-Antitubulin Activity Relationships in Steganacin Congeners and Analogues. Inhibition of Tubulin Polymerization in Vitro by (±)-Isodeoxypodophyllotoxin. J. Med. Chem. 1980, 23, 546-549.